Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OLX75016
- Development stage
- Unknown
- Lead developer
- Olix Pharmaceuticals
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
OLX75016 is an investigational small interfering RNA (siRNA) therapeutic developed by OliX Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH), with accompanying liver fibrosis and for weight management. The drug utilizes proprietary RNA interference (RNAi) technology, specifically GalNAc-conjugated asymmetric siRNA (asiRNA), to down-regulate the expression of disease-causing genes implicated in liver fat accumulation, inflammation, and fibrosis. Preclinical studies have shown that OLX75016 reduces liver fat content, inflammation, and fibrosis in obese models. It has demonstrated enhanced weight loss effects when combined with GLP-1 receptor agonists such as semaglutide and may mitigate weight rebound after cessation of GLP-1 therapy. The mechanism is differentiated from existing therapies by targeting gene expression rather than acting directly on metabolic receptors or hormones[1][5][6][8].
- Other names
- OLX-75016OLX75016OLX 75016
Beyond the preview
Go deeper on OLX75016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OLX75016.